Eczema drug switch study halted early – only 7 patients enrolled
NCT ID NCT06773455
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study looked at whether tralokinumab could help adults with moderate-to-severe eczema who had not improved enough with dupilumab. Only 7 people took part before the study was stopped early. Participants received tralokinumab injections every two weeks for 24 weeks, and the main goal was to see how many achieved clear or almost clear skin by week 16.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Psoriasis Treatment Center of New Jersey
East Windsor, New Jersey, 08520, United States
Conditions
Explore the condition pages connected to this study.